Nianxiang Zou

Array ( [id] => 18107964 [patent_doc_number] => 20230000844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => BIOMARKERS FOR NANOPARTICLE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/775562 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868512 [patent_doc_number] => 20210161979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/084841 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671339 [patent_doc_number] => 20210060102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH BEVACIZUMAB [patent_app_type] => utility [patent_app_number] => 16/949331 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316013 [patent_doc_number] => 12454555 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Engineered influenza antigenic polypeptides and immunogenic compositions thereof [patent_app_type] => utility [patent_app_number] => 17/075985 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 25287 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 341 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316013 [patent_doc_number] => 12454555 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Engineered influenza antigenic polypeptides and immunogenic compositions thereof [patent_app_type] => utility [patent_app_number] => 17/075985 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 25287 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 341 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17075985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621505 [patent_doc_number] => 20210040158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => RECOMBINANT VIRAL VECTORS [patent_app_type] => utility [patent_app_number] => 17/074358 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020593 [patent_doc_number] => 20220372092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/769839 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -147 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18762950 [patent_doc_number] => 11813329 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Method and composition for treating cancer or skin lesion using a vaccine [patent_app_type] => utility [patent_app_number] => 17/068087 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14112 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18110850 [patent_doc_number] => 20230003730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA [patent_app_type] => utility [patent_app_number] => 17/766015 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18110850 [patent_doc_number] => 20230003730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA [patent_app_type] => utility [patent_app_number] => 17/766015 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051348 [patent_doc_number] => 20240093317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => A MOLECULAR SENSING PLATFORM AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/767837 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051348 [patent_doc_number] => 20240093317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => A MOLECULAR SENSING PLATFORM AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/767837 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18288923 [patent_doc_number] => 11617780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-04 [patent_title] => Antigenic Epstein Barr virus polypeptides [patent_app_type] => utility [patent_app_number] => 17/061146 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 90 [patent_no_of_words] => 23526 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596669 [patent_doc_number] => 20210023200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => RSV F Protein Mutants [patent_app_type] => utility [patent_app_number] => 17/060944 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17060944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19235002 [patent_doc_number] => 20240192196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => NOVEL CORONAVIRUS SARS-CoV-2 SAFE REPLICON SYSTEM AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/021348 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19235002 [patent_doc_number] => 20240192196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => NOVEL CORONAVIRUS SARS-CoV-2 SAFE REPLICON SYSTEM AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/021348 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575498 [patent_doc_number] => 11732012 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Attenuated strains of oncolytic rhabdovirus and uses thereof in tumor treatment [patent_app_type] => utility [patent_app_number] => 17/030737 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 10 [patent_no_of_words] => 9723 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960405 [patent_doc_number] => 20220340985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => MATERIALS AND METHODS FOR DETECTING HUMAN PAPILLOMA VIRUS [patent_app_type] => utility [patent_app_number] => 17/761064 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710407 [patent_doc_number] => 20210077554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells [patent_app_type] => utility [patent_app_number] => 17/020670 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17020670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18014378 [patent_doc_number] => 11506667 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Serologic test for therapy control of HPV16 positive carcinoma [patent_app_type] => utility [patent_app_number] => 17/015955 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 4747 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015955 [rel_patent_id] =>[rel_patent_doc_number] =>)